Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 5/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 6/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095748 | 0.92 | JAK3 (0.51) | JAK3MAPTHTTLMNACA2 | |
| SCHEMBL3100385 | 0.91 | MEN1 (0.45) | MAPTCA2CA9CA12CA1 | |
| SCHEMBL3094741 | 0.90 | MEN1 (0.44) | MAPTCA2CA9CA12CA1 | |
| SCHEMBL3097301 | 0.88 | NPC1 (0.42) | IDH1CA2ALDH1A1 | |
| SCHEMBL3097193 | 0.86 | CA2 (0.43) | MAPTHTTLMNACA2CA9 | |
| SCHEMBL3095867 | 0.84 | MEN1 (0.45) | MAPTLMNACA2CA9CA12 | |
| SCHEMBL3100409 | 0.84 | NPC1 (0.42) | MAPTLMNACA2CA9CA12 | |
| SCHEMBL3084068 | 0.83 | CA12 (0.52) | MAPTHTTLMNACA2CA9 | |
| SCHEMBL3105677 | 0.81 | RAB9A (0.43) | MAPTCA2CA9CA12CA1 | |
| SCHEMBL3100462 | 0.79 | CA12 (0.49) | MAPTLMNACA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | claimed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | claimed |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2010-09-16 | — | — | US | disclosed |
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BAYER HEALTHCARE LLC (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016295-A1 | Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity | BCAT2, BCAT1, FABP4 | IDH1 3463/4885JAK3 1323/4885MAPT 3315/4885 |
| US-20100234307-A1 | PREPARATION AND USE OF BIPHENYL AMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BCAT2, BCAT1, FABP4 | IDH1 3463/4885JAK3 1323/4885MAPT 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.